Clinical Trials Logo

Filter by:
NCT ID: NCT05703126 Recruiting - Clinical trials for Endothelial Dysfunction

Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

Acute myeloid leukemia (AML) is a clonal neoplastic disease of the hematopoietic tissue associated with a mutation in the precursor cell of hematopoiesis, which results in a differentiation block and uncontrolled proliferation of immature myeloid cells. Anthracycline antibiotics have been an integral part of the treatment of acute myeloid leukemia since the 1970s. However, the clinical usefulness of anthracyclines is limited primarily by the high incidence of cardiotoxicity. According to the European Society of Cardiology guidelines for cardio-oncology, cardiovascular toxicity is defined as any impairment of cardiac function associated with anticancer treatment, as the term encompasses both a wide range of possible clinical manifestations and an etiological relationship with various treatments, including chemotherapy, radiation therapy, immunotherapy and treatment with targeted drugs. Cardiovascular toxicity can be acute, subacute or delayed, manifesting many years after chemotherapy or radiation therapy, involving a number of cardiac structures, which can lead to the development of heart failure, coronary heart disease, valvular heart disease, arrhythmias, including cardiac conduction disorders and diseases of the pericardium. Anthracycline-induced cardiotoxicity is the negative effect of anthracyclines on normal cardiac activity due to their toxic effects on the heart muscle and the cardiac conduction system. Anthracycline-induced cardiotoxicity manifests as asymptomatic left ventricular dysfunction in 57% of treated patients and restrictive or dilated cardiomyopathy leading to congestive heart failure (CHF) in 16% to 20% of patients. Anthracycline-induced congestive heart failure is often resistant to therapy and has a mortality rate of up to 79%. Thus, there is a need for early detection of cardiovascular dysfunction associated with chemotherapy treatment of acute myeloid leukemia in order to timely prescribe drug therapy. Purpose of the study To optimize the early detection of endothelial dysfunction and left ventricular myocardial contractility in patients with acute myeloid leukemia during chemotherapy treatment based on a comprehensive assessment of instrumental and laboratory research parameters. Expected results Based on a comprehensive analysis using laser Doppler flowmetry, stress echocardiography with the determination of global longitudinal strain of the myocardium, biochemical markers of endothelial damage and cardiac biomarkers, a correlation between violations of the contractility of the left ventricular myocardium and violations of the vasoregulatory function of the vascular endothelium will be revealed, which will allow developing an algorithm for early detection of cardiomyopathy and vascular complications in patients with acute myeloid leukemia during chemotherapy treatment.

NCT ID: NCT05697575 Not yet recruiting - Acute Stroke Clinical Trials

Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice

REPIN
Start date: February 1, 2023
Phase:
Study type: Observational [Patient Registry]

The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.

NCT ID: NCT05696067 Active, not recruiting - COVID-19 Clinical Trials

Evaluation of Corfluvec Vaccine for the Prevention of COVID-19 in Healthy Volunteers

Start date: September 13, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the study is to investigate the safety and immunogenicity of a two-component intranasal vaccine for the prevention of COVID-19 in healthy volunteers 18-60 years old

NCT ID: NCT05695859 Enrolling by invitation - Clinical trials for Breast Cancer Female

99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy

Start date: December 20, 2022
Phase:
Study type: Observational

An open-label, single center study with 99mTc-DARPinG3 SPECT/CT and biopsies of primary tumour and metastatic lymph nodes in breast cancer patients, where the primary endpoint of the study is to find out the correlation between the HER2 expression measured by 99mTc-DARPinG3 SPECT/CT and standard histopathology from relevant tumor and lymph node biopsies.

NCT ID: NCT05695001 Recruiting - Clinical trials for Acute Pancreatitis With Uninfected Necrosis, Unspecified

Hemoperfusion Efferon СT for the Treatment of Patients With Acute Pancreatitis

Start date: January 1, 2022
Phase:
Study type: Observational

Mortality from severe acute pancreatitis reaches 42%. The prognosis of acute pancreatitis is associated with the development of acute inflammatory response syndrome (SIRS) and multiple organ failure (MOF). Due to the lack of etiological therapy, the treatment of acute pancreatitis is predominantly symptomatic. Severity and mortality are associated with early systemic inflammatory response syndrome (SIRS) and septic complications at a later stage of the disease. With regard to the pronounced inflammatory response ("cytokine storm") during the early phase of endogenous intoxication of acute pancreatitis, extracorporeal removal of cytokines is a promising therapeutic approach. This prospective study examines the effect of early extracorporeal sorption of cytokines using the Efferon CT device on the severity of clinical symptoms of endogenous intoxication in acute pancreatitis and aseptic pancreatic necrosis.

NCT ID: NCT05694988 Recruiting - Clinical trials for Acute Pancreatitis Without Necrosis or Infection

Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Mortality from severe acute pancreatitis reaches 42%. The prognosis of acute pancreatitis is associated with the development of acute inflammatory response syndrome (SIRS) and multiple organ failure (MOF). Due to the lack of etiological therapy, the treatment of acute pancreatitis is predominantly symptomatic. Severity and mortality are associated with early systemic inflammatory response syndrome (SIRS) and septic complications in the later stages of the disease. In connection with a pronounced inflammatory reaction ("cytokine storm") in the early phase of endogenous intoxication of acute pancreatitis, a promising therapeutic approach is the extracorporeal removal of cytokines. This prospective study intends to study the effect of hemoperfusion (Efferon CT) in combination with high-volume hemofiltration (HVHF) on the severity of symptoms of endogenous intoxication and indicators of organ dysfunction in acute pancreatitis.

NCT ID: NCT05693181 Recruiting - Clinical trials for Spinal Cord Injury, Acute

Cord Blood Cells in Patients With Acute SCI

SUBSCI II
Start date: December 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective, single-blinded, single-center, randomized, comparative, interventional clinical study of systemic mononuclear multiple allogenic cord blood cells administration safety and efficiency in patients having acute severe contusion spinal cord injury (ASIA A/B), phase I/II

NCT ID: NCT05690490 Active, not recruiting - Clinical trials for Endoscopic Mucosal Resection With Circumferential Incision

Endoscopic Mucosal Resection With Circumferential Incision for Colorectal Neoplasms

C-EMR
Start date: November 27, 2020
Phase: N/A
Study type: Interventional

This is a prospective randomized trial to improve the results of treatment of patients with colorectal neoplasms.

NCT ID: NCT05690009 Not yet recruiting - Hypertension Clinical Trials

Real Clinical Practice Register of AlbUminuRia Detection in Patients With Previously undiAgnosed Chronic Kidney Disease

AURA
Start date: January 20, 2023
Phase:
Study type: Observational [Patient Registry]

Real clinical practice register of Albuminuria detection in patients with previously undiagnosed chronic kidney disease

NCT ID: NCT05689827 Completed - COVID-19 Clinical Trials

Safety and Efficacy of the Therapy With BREINMAX® for the Treatment of Patients With Asthenia After COVID-19

Start date: April 5, 2022
Phase: Phase 4
Study type: Interventional

This is prospective multicentre comparative randomized double blind placebo controlled study conducted in 6 medical facilities.The objective of the study is to assess the safety and efficacy of the sequential therapy with BREINMAX®, solution for intravenous infusion and intramuscular injection, and BREINMAX®, capsules for the treatment of patients with asthenia after having the novel coronavirus infection (COVID-19)